MBNL1 and myotonic dystrophy type 1: Recent potential therapeutic approaches for DM1 have ranged from overexpression of MBNL1, RNA interference against the CUG repeats, CAG oligonucleotides, and small chemical compounds that bind to the CUG RNA and displace MBNL1 from RNA foci9, 35, 36, 37.